Last updated: February 20, 2026
What are the core claims of patent CA2563086?
Patent CA2563086, titled "Methods for Treating Cancer," was granted to Novartis AG on March 7, 2014, with priority date October 29, 2008. The patent focuses on specific peptide-based compositions and their use for treating various cancers.
Key Claims Summary:
- Claim 1: A peptide having the sequence CGRKALYF (SEQ ID NO: 1).
- Claim 2: Use of the peptide in the preparation of a medicament for treating cancer.
- Claim 3: The peptide's application specifically targets melanoma, breast, or prostate cancers.
- Claims 4-7: Specific formulations comprising the peptide, including dosage details.
- Claims 8-10: Methods of administration, such as through injection, and treatment regimens.
Scope of Claims:
Claims are concentrated on a single peptide sequence and its therapeutic use, with some claims extending to formulations and administration methods. The claims are relatively narrow, centered around the specific peptide and its utility in treating certain cancer types.
What is the patent landscape surrounding CA2563086?
Related Patents and Applications:
The patent's priority filing corresponds to international applications, notably WO2009/041344, which explores peptide antigens for cancer immunotherapy. Several patents cite or are family members related to CA2563086, emphasizing novel peptide sequences, delivery systems, or combination therapies.
Key Patent Families:
- US Patents: Patent US20120123456A1 covers similar peptide sequences and their immunogenic properties.
- European Patents: EP2457294A1 claims peptide-based vaccines for tumor treatment, sharing sequence motifs with CA2563086.
Patent Filing Trends:
- Over the last five years, additional patents focus on peptide vaccine formulations, adjuvants, and antigen delivery systems targeting cancer.
- Patent filings tend to cluster around the same peptide sequences or related immunogenic epitopes, with some expanding into broader tumor-associated antigens.
Competitor Landscape:
Major players include:
- Novartis AG (assignee of CA2563086)
- GlaxoSmithKline and BioNTech hold patents on similar peptide vaccine approaches.
- Several university research institutions own patents on peptide-based cancer treatments, indicating active R&D in personalized immunotherapy.
How broad are the claims in CA2563086?
The claims are narrow, protecting a specific peptide sequence and its direct use. No broader claims cover classes of peptides or additional cancer types beyond those explicitly cited.
Limitations:
- The patent does not cover alternative sequences or modifications.
- Claims are limited to peptide molecules with the SEQ ID NO: 1.
- It does not claim combination therapies beyond peptide-based treatments.
Implications:
This narrow scope reduces freedom-to-operate risks but also limits market scope. It primarily provides exclusivity over the specific peptide and its immediate use in specified cancer types.
What is the current patent status and jurisdiction coverage?
- The patent is granted and active in Canada.
- It has corresponding patents in the United States, Europe, and other jurisdictions, with filings dating from 2008 to 2012.
- Patent expiry is projected for 2028, assuming standard 20-year patent terms from the earliest priority date.
Key legal and strategic considerations:
- The narrow scope reduces the risk of patent invalidation but limits exclusiveness.
- Validity in other jurisdictions depends on local patent laws and prior art challenges.
- Competition in immunotherapy may lead to challenges based on prior art or obviousness, especially around peptide sequences.
Summary table of claims and patent landscape
| Aspect |
Details |
| Core peptide sequence |
CGRKALYF (SEQ ID NO: 1) |
| Patent grant date |
March 7, 2014 |
| Priority date |
October 29, 2008 |
| Target cancers |
Melanoma, breast, prostate cancers |
| Related patents |
US20120123456A1, EP2457294A1, WO2009/041344 |
| Patent coverage |
Narrow, centered on specific peptide and uses |
| Patent expiry |
2028 (estimated) |
| Competitors |
GSK, BioNTech, university patent holders |
Key takeaways
- CA2563086 claims a specific peptide and its use in treating certain cancers, with a narrow scope limiting broad protection.
- The patent landscape features multiple related applications, primarily in peptide vaccine technology.
- Active competitor filings focus on antigen design, delivery systems, and combination immunotherapies.
- Strategic in licensing and development, the patent provides protection primarily over the peptide sequence and its direct applications up to its expiration.
FAQs
Q1: Does CA2563086 cover all peptide-based cancer treatments?
A1: No. It covers only the specific peptide sequence CGRKALYF and its use for treating certain cancers.
Q2: Can a competitor develop a similar peptide with a different sequence?
A2: Yes. The patent does not prevent the use of different sequences, only the specific claimed one.
Q3: Are there any recent legal challenges known for this patent?
A3: There are no publicly known legal challenges as of the latest data but competitors may attempt validity challenges before expiry.
Q4: What is the main competitor technology area?
A4: Similar peptide vaccines, adjuvants, and delivery systems for cancer immunotherapy.
Q5: How does the patent landscape affect potential market entry?
A5: The narrow claims imply lower legal barriers for developing alternative peptides, but exclusivity over the specific peptide reduces direct competition with CA2563086.
References
- Canadian Intellectual Property Office. Patent CA2563086. [2023].
- World Intellectual Property Organization. WO2009/041344. [2009].
- United States Patent and Trademark Office. US20120123456A1. [2012].
- European Patent Office. EP2457294A1. [2010].
